JP2018505158A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505158A5
JP2018505158A5 JP2017536879A JP2017536879A JP2018505158A5 JP 2018505158 A5 JP2018505158 A5 JP 2018505158A5 JP 2017536879 A JP2017536879 A JP 2017536879A JP 2017536879 A JP2017536879 A JP 2017536879A JP 2018505158 A5 JP2018505158 A5 JP 2018505158A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
odd
chain fatty
fatty acids
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017536879A
Other languages
English (en)
Other versions
JP7064879B2 (ja
JP2018505158A (ja
Filing date
Publication date
Priority claimed from US14/591,660 external-priority patent/US9561206B2/en
Application filed filed Critical
Publication of JP2018505158A publication Critical patent/JP2018505158A/ja
Publication of JP2018505158A5 publication Critical patent/JP2018505158A5/ja
Application granted granted Critical
Publication of JP7064879B2 publication Critical patent/JP7064879B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (16)

  1. 1つまたは複数の奇数鎖脂肪酸またはその医薬的に許容され得る塩、および
    医薬的に許容され得るキャリア
    を含む医薬組成物。
  2. 前記1つまたは複数の奇数鎖脂肪酸がヘプタデカン酸である、請求項1に記載の医薬組成物。
  3. 偶数鎖脂肪酸を実質的に含まない、請求項1〜2のいずれか一項に記載の医薬組成物。
  4. 複数の奇数鎖脂肪酸を含む、請求項1〜3のいずれか一項に記載の医薬組成物。
  5. 単位投薬形態である、請求項1〜4のいずれか一項に記載の医薬組成物。
  6. 1kgの体重あたり2.5mg〜11mgの前記1つまたは複数の奇数鎖脂肪酸またはその医薬的に許容され得る塩を患者に投与するために構成される、請求項1〜5のいずれか一項に記載の医薬組成物。
  7. 1日あたり1回の投与のために構成される、請求項1〜6のいずれか一項に記載の医薬組成物。
  8. 0.01mg〜10000mgの前記1つまたは複数の奇数鎖脂肪酸またはその医薬的に許容され得る塩を含む、請求項1〜7のいずれか一項に記載の医薬組成物。
  9. 前記1つまたは複数の奇数鎖脂肪酸が1つまたは複数の奇数鎖飽和脂肪酸である、請求項1に記載の医薬組成物
  10. 代謝症候群、心臓血管疾患、糖尿病、2型糖尿病、多嚢胞性卵巣症候群、脂肪肝、コレステロール胆石、喘息、睡眠障害、ガン、腹部肥満、血圧上昇、上昇した空腹時血漿グルコース、上昇した血清トリグリセリド、低下した高密度リポタンパク質レベル、前炎症性状態、C反応性タンパク質の上昇、血栓形成促進性状態、高フェリチン血症、鉄過剰症を伴う高フェリチン血症、又は鉄過剰症を伴わない高フェリチン血症の処置または予防のための、請求項1〜のいずれか一項に記載される医薬組成物
  11. 高フェリチン血症の処置または予防のための、請求項10に記載の医薬組成物
  12. 代謝症候群の処置または予防のための、請求項10に記載の医薬組成物
  13. 前記医薬組成物が、代謝症候群のマーカーまたは代謝症候群の症状を調節するために構成される、請求項12に記載の医薬組成物
  14. 代謝症候群の前記マーカーが、奇数鎖脂肪酸割合、奇数鎖脂肪酸の血清中濃度、奇数鎖脂肪酸の赤血球膜中濃度、血清中の総奇数鎖脂肪酸、赤血球膜中の総奇数鎖脂肪酸、血清フェリチン、血清鉄、トランスフェリチン飽和度、血清グルコース、血清トリグリセリド、血圧、アディポネクチン、HDLコレステロール、尿中微量アルブミン、CRP、IL−6、TNFα、c−Jun N末端キナーゼ、ATMおよび単球走化性タンパク質−1からなる群から選択される、請求項13に記載の医薬組成物
  15. 前記医薬組成物が、前記1つまたは複数の奇数鎖脂肪酸の血清中濃度または赤血球膜中濃度を処置前の値よりも少なくとも約0.01×10−4Mだけ増大させるために構成される、請求項10〜14のいずれか一項に記載の医薬組成物
  16. 1日あたり、1kgの体重あたり2.5mg〜11mgの前記医薬組成物が、前記患者に投与され、及び/又は、
    前記医薬組成物が前記患者に1日あたり1回投与される、請求項10〜15のいずれか一項に記載の医薬組成物
JP2017536879A 2015-01-07 2015-12-21 代謝症候群の診断および処置のための組成物および方法 Active JP7064879B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/591,660 2015-01-07
US14/591,660 US9561206B2 (en) 2015-01-07 2015-01-07 Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
PCT/US2015/067172 WO2016111843A1 (en) 2015-01-07 2015-12-21 Compositions and methods for diagnosis and treatment of metabolic syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020002588A Division JP2020055875A (ja) 2015-01-07 2020-01-10 代謝症候群の診断および処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2018505158A JP2018505158A (ja) 2018-02-22
JP2018505158A5 true JP2018505158A5 (ja) 2019-01-24
JP7064879B2 JP7064879B2 (ja) 2022-05-11

Family

ID=55085946

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017536879A Active JP7064879B2 (ja) 2015-01-07 2015-12-21 代謝症候群の診断および処置のための組成物および方法
JP2020002588A Pending JP2020055875A (ja) 2015-01-07 2020-01-10 代謝症候群の診断および処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020002588A Pending JP2020055875A (ja) 2015-01-07 2020-01-10 代謝症候群の診断および処置のための組成物および方法

Country Status (6)

Country Link
US (6) US9561206B2 (ja)
EP (2) EP4410285A2 (ja)
JP (2) JP7064879B2 (ja)
AR (1) AR103371A1 (ja)
TW (1) TW201639557A (ja)
WO (1) WO2016111843A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022347B2 (en) * 2015-01-07 2018-07-17 The United States Of America, As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of metabolic syndrome
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
WO2018089773A1 (en) * 2016-11-10 2018-05-17 Fractyl Laboratories, Inc. Systems, devices, and methods for performing medical procedures in the intestine
US10307388B2 (en) * 2016-12-29 2019-06-04 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of inflammation
US10238618B2 (en) * 2016-12-29 2019-03-26 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of anemia
AU2018354090A1 (en) 2017-10-23 2020-03-12 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
JP7492459B2 (ja) * 2018-05-16 2024-05-29 エピトラッカー インコーポレイテッド 加齢に関連する状態の診断及び治療のための組成物及び方法
EP3796976A4 (en) 2018-05-23 2022-03-30 Epitracker, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO LONGEVITY AND QUALITY OF AGING
CN110129400B (zh) * 2019-05-25 2023-09-01 华南理工大学 一种提高微生物油脂奇数碳链脂肪酸含量的方法
AU2021329343A1 (en) * 2020-08-20 2023-03-09 Epitracker, Inc. Compositions and methods for treatment of obesity
EP4426130A1 (en) 2021-11-03 2024-09-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
CN115894217A (zh) * 2022-10-19 2023-04-04 福建农林大学 一种具有降血糖作用的十七烷酸的制备与应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2615061A1 (de) 1976-04-05 1977-10-06 Wolfgang Dr Med Wagner Injektionsverfahren und -vorrichtungen
US4252159A (en) 1979-04-02 1981-02-24 Maki Eugene B Dosage device
JPS60172925A (ja) * 1984-02-17 1985-09-06 Kao Corp 胆石溶解剤
JPS6115809A (ja) * 1984-06-29 1986-01-23 Lion Corp 細胞賦活剤
DE3501534A1 (de) 1984-09-22 1986-05-15 Walter Ing.(grad.) 7758 Meersburg Holzer Verfahren und vorrichtung zum dosieren von insulin oder aehnlichen langzeitmedikamenten
JPS6212716A (ja) * 1985-07-11 1987-01-21 Nippon Oil & Fats Co Ltd 制がん剤
DE3875075D1 (de) 1987-11-25 1992-11-05 Siemens Ag Dosiergeraet zum gesteuerten injizieren von fluessigkeiten aus einem vorratsbehaelter in einen organismus.
EP0569618B1 (de) 1992-05-12 1997-01-02 Siemens-Elema AB Dosiergerät zur gesteuerten Abgabe einer Flüssigkeit
JP3558351B2 (ja) * 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
AUPN137895A0 (en) * 1995-02-27 1995-03-16 Clover Corporation Pty Ltd Composition and method
JP2003160486A (ja) 2001-09-17 2003-06-03 Lion Corp 経口養育毛剤及び該養育毛剤を含有する飲食品
US20030203042A1 (en) * 2002-04-24 2003-10-30 Cook Lisa Ann Compositions comprising milk protein concentrate and fatty acid and processes of their preparation
US20030203004A1 (en) 2002-04-24 2003-10-30 Kelm Gary Robert Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
WO2005099483A1 (en) 2004-04-16 2005-10-27 Indevex Ab Ingestible composition
US7651845B2 (en) 2004-05-13 2010-01-26 The Regents Of The University Of California Method and apparatus for glucose control and insulin dosing for diabetics
WO2005120484A1 (ja) 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
CA2483675A1 (en) 2004-10-01 2006-04-01 Jens Peschardt Food bar
US8251904B2 (en) 2005-06-09 2012-08-28 Roche Diagnostics Operations, Inc. Device and method for insulin dosing
JP2008255022A (ja) 2007-04-02 2008-10-23 Kureha Corp 抗癌性物質
DE102007055636A1 (de) 2007-11-21 2009-05-28 Robert Bosch Gmbh Medikamenten-Dosiervorrichtung zum Verabreichen eines flüssigen Medikaments
US20110098358A1 (en) 2008-06-11 2011-04-28 Ricom Corporation Human beta3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
JP2010260833A (ja) 2009-05-11 2010-11-18 Daicho Kikaku:Kk 抗自己免疫疾患剤
MX348036B (es) * 2009-12-30 2017-05-24 Baylor Res Institute Terapia anaplerótica para la enfermedad de alzheimer y el cerebro envejecido.
US20120072236A1 (en) 2010-08-06 2012-03-22 Benjamin Atkin Insulin pen data recording and transmission device
GB201020133D0 (en) * 2010-11-26 2011-01-12 Royal Holloway & Bedford New College Therapeutic use of compounds
WO2012108954A2 (en) 2011-02-09 2012-08-16 Becton, Dickinson And Company Nighttime basal dosing device
ITMI20111284A1 (it) * 2011-07-11 2013-01-12 Giovanni Nusca Composizione farmaceutica.
EP3217879B1 (en) * 2014-11-11 2020-01-08 Koninklijke Philips N.V. Source-detector arrangement
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
US9662306B2 (en) * 2015-01-07 2017-05-30 The United States Of America, As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of metabolic syndrome
US10022347B2 (en) * 2015-01-07 2018-07-17 The United States Of America, As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of metabolic syndrome
US10307388B2 (en) 2016-12-29 2019-06-04 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of inflammation
US10238618B2 (en) 2016-12-29 2019-03-26 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of anemia
JP7001554B2 (ja) * 2018-06-27 2022-01-19 ヤンマーパワーテクノロジー株式会社 クレーン機能付き油圧ショベル

Similar Documents

Publication Publication Date Title
JP2018505158A5 (ja)
Wu et al. Pseudoephedrine/ephedrine shows potent anti-inflammatory activity against TNF-α-mediated acute liver failure induced by lipopolysaccharide/d-galactosamine
HRP20192291T1 (hr) Bardoksolon-metil, namijenjen liječenju pretilosti
Parlevliet et al. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet
JP2013509429A5 (ja)
RU2018133298A (ru) Способы применения агонистов fxr
FI2981255T3 (fi) Empagliflotsiinin terapeuttiset käytöt
JP2009215293A5 (ja)
JP2015503593A5 (ja)
JP2015518818A5 (ja)
JP2020502156A5 (ja)
AR103371A1 (es) Composiciones y métodos para diagnosis y tratamiento de síndrome metabólico, uso
RU2018136872A (ru) Композиции, содержащие 15-oh эпк, и способы их применения
JP2010515682A5 (ja)
JP2017519028A5 (ja)
RU2018140900A (ru) Семаглутид при сердечно-сосудистых состояниях
JP2017014206A5 (ja)
JP2014533701A5 (ja)
JP2015514797A5 (ja)
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
JP2011157375A5 (ja)
JP2013501049A5 (ja)
JP2017512194A5 (ja)
JP2015501832A5 (ja)
Elahi et al. Long-term statin administration to dams on high-fat diet protects not only them but also their offspring from cardiovascular risk